Felix Biotechnology
We’re creating programmable therapies
Y CombinatorWinter 2020InactiveHealthcareDrug Discovery and DeliveryBiotechGenomicsTherapeutics
What they do
Problem
Antimicrobial resistance is rising and there is a need for new, rapidly designable therapies to combat drug-resistant infections.
Solution
An end-to-end digital platform that designs and programs viral-based therapies to target pathogens.
Who it's for
Pharmaceutical and biotechnology companies and research organizations developing therapeutics for infectious diseases.
Founders
Robert McBride
Founder
Vivek Mutalik
Founder
Paul Turner
Founder
Company timeline
- Founded2019
- YC batchWinter 2020
- StatusInactive
- Team size6 people
- LocationSan Francisco, CA, USA
Similar startups
General Proximity
The next generation of induced-proximity medicines.
Sigma Genetics
Sigma Genetics is a biotechnology company that is building…
Asher Bio
We build better immunotherapies
Reverie Labs
Engineering next-generation, brain-penetrant cancer therapies.
Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…